SCHEMBL934969

SCHEMBL934969

O=C(Cl)C(Sc1ccc(Br)cc1)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.49
EPHX1 P07099 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.45
PKM P14618 1/20 0.45
ALDH1A1 P00352 3/20 0.43
MAPT P10636 3/20 0.42
GAA P10253 2/20 0.42
MAPK1 P28482 1/20 0.42
KDM4E B2RXH2 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
S1PR3 Q99500 1/20 0.41
PAX8 Q06710 1/20 0.41
POLB P06746 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ADAM17 P78536 1/20 0.40
TSHR P16473 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL934473 0.88 LMNA (0.61) LMNAEPHX1SMN1; SMN2PKMALDH1A1
SCHEMBL11564640 0.86 LMNA (0.51) LMNAEPHX1SMN1; SMN2PKMALDH1A1
SCHEMBL933431 0.85 CYP2C9 (0.53) LMNAEPHX1SMN1; SMN2PKMALDH1A1
SCHEMBL5420619 0.83 LMNA (0.53) LMNASMN1; SMN2PKMALDH1A1MAPT
SCHEMBL933324 0.78 EPHX1 (0.44) LMNAEPHX1SMN1; SMN2PKMALDH1A1
SCHEMBL933787 0.75 HSD17B10 (0.53) LMNASMN1; SMN2MAPTL3MBTL1MEN1
SCHEMBL934324 0.74 EPHX1 (0.51) LMNAEPHX1SMN1; SMN2PKMALDH1A1
SCHEMBL6782198 0.73 MEN1 (0.45) LMNAEPHX1SMN1; SMN2PKMALDH1A1
SCHEMBL28203714 0.73 MEN1 (0.44) SMN1; SMN2MEN1KMT2A
SCHEMBL11562132 0.72 CYP2C9 (0.59) LMNAEPHX1SMN1; SMN2PKMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088800-A1 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS ALLERGAN, INC. (US) 2012-04-12 US disclosed
WO-2011008475-A1 OPTIONALLY SUBSTITUTED 2-(ARYLMETHYL, ARYLOXY OR ARYLTHIO) -N- PYRIDIN-2 -YL-ARYL ACETAMIDE OR 2, 2-BIS (ARYL) -N-PYRIDIN-2-YL ACETAMIDE COMPOUNDS AS MEDICAMENTS FOR THE TREATMENT OF EYE DISEASES ALLERGAN, INC. (US) 2011-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088800-A1 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS S1PR3, S1PR5, S1PR1 LMNA 2211/4885EPHX1 1163/4885SMN1; SMN2 3896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.